Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy
Approximately, 20% of patients with pancreatic ductal adenocarcinoma have resectable disease at diagnosis. Given improvements in locoregional and systemic therapies, some patients with borderline resectable pancreatic cancer (BRPC) can now undergo successful resection. The outcomes of patients with BRPC after neoadjuvant therapy remain unclear.
A prospectively maintained single-institution database was utilized to identify patients with BRPC who were managed at the Johns Hopkins Pancreas Multidisciplinary Clinic (PMDC) between 2013 and 2016. BRPC was defined as any tumor that presented with radiographic evidence of the involvement of the portal vein (PV) or superior mesenteric vein (SMV) that was deemed to be technically resectable (with or without the need for reconstruction), or the abutment (< 180° involvement) of the common hepatic artery (CHA) or superior mesenteric artery (SMA), in the absence of involvement of the celiac axis (CA). We collected data on treatment, the course of the disease, resection rate, and survival.
Of the 866 patients evaluated at the PMDC during the study period, 151 (17.5%) were staged as BRPC. Ninety-six patients (63.6%) underwent resection. Neoadjuvant chemotherapy was administered to 142 patients (94.0%), while 78 patients (51.7%) received radiation therapy in the neoadjuvant setting. The median overall survival from the date of diagnosis, of resected BRPC patients, was 28.8 months compared to 14.5 months in those who did not (p < 0.001). Factors associated with increased chance of surgical resection included lower ECOG performance status (p = 0.011) and neck location of the tumor (p = 0.001). Forty-seven patients with BRPC (31.1%) demonstrated progression of disease; surgical resection was attempted and aborted in 12 patients (7.9%). Eight patients (5.3%) were unable to tolerate chemotherapy; six had disease progression and two did not want to pursue surgery. Lastly, four patients (3.3%) were conditionally unresectable due to medical comorbidities at the time of diagnosis due to comorbidities and failed to improve their status and subsequently had progression of the disease.
After initial management, 31.1% of patients with BRPC have progression of disease, while 63.6% of all patients successfully undergo resection, which was associated with improved survival. Factors associated with increased likelihood of surgical resection include lower ECOG performance status and tumor location in the neck.
KeywordsBorderline pancreatic cancer Neoadjuvant therapy Rate of resectability (Denominator) Survival
- 3.Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA et al. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgery. 2018. https://doi.org/10.1097/SLA.0000000000002734.
- 4.Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN. 2017;15(8):1028–61. https://doi.org/10.6004/jnccn.2017.0131.CrossRefGoogle Scholar
- 5.Javed AA, Bleich K, Bagante F, He J, Weiss MJ, Wolfgang CL et al. Pancreaticoduodenectomy with venous resection and reconstruction: current surgical techniques and associated postoperative imaging findings. Abdominal Radiology (New York). 2017. https://doi.org/10.1007/s00261-017-1290-5.
- 8.McClaine RJ, Lowy AM, Sussman JJ, Schmulewitz N, Grisell DL, Ahmad SA. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB: the Official Journal of the International Hepato Pancreato Biliary Association. 2010;12(1):73–9. https://doi.org/10.1111/j.1477-2574.2009.00136.x.CrossRefGoogle Scholar
- 9.Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Annals of Surgical Oncology. 2015;22(4):1153–9. https://doi.org/10.1245/s10434-014-4225-1.CrossRefGoogle Scholar
- 13.Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. Journal of the American College of Surgeons. 2008;206(5):833–46; discussion 46–8. https://doi.org/10.1016/j.jamcollsurg.2007.12.020.CrossRefGoogle Scholar
- 14.Isaji S, Mizuno S, Windsor JA, Bassi C, Fernandez-Del Castillo C, Hackert T et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology: official journal of the International Association of Pancreatology. 2018;18(1):2–11. https://doi.org/10.1016/j.pan.2017.11.011.CrossRefGoogle Scholar
- 15.Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH et al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Annals of Surgery. 2018. https://doi.org/10.1097/SLA.0000000000002705.
- 17.Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008;26(21):3496–502. https://doi.org/10.1200/JCO.2007.15.8634.CrossRefGoogle Scholar
- 18.Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Medicine. 2010;7(4):e1000267. https://doi.org/10.1371/journal.pmed.1000267.CrossRefGoogle Scholar
- 19.Blair AB, Rosati LM, Rezaee N, Gemenetzis G, Zheng L, Hruban RH et al. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. Surgery. 2018;163(5):1090–6. https://doi.org/10.1016/j.surg.2017.11.027.CrossRefGoogle Scholar
- 20.Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers. 2018;10(1). https://doi.org/10.3390/cancers10010024.
- 22.Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, Collisson E et al. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surgery. 2016;151(8):e161137. https://doi.org/10.1001/jamasurg.2016.1137.CrossRefGoogle Scholar
- 23.Quan K, Sutera P, Xu K, Bernard ME, Burton SA, Wegner RE et al. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma. Practical Radiation Oncology. 2018;8(2):95–106. https://doi.org/10.1016/j.prro.2017.10.001.CrossRefGoogle Scholar
- 24.Kim HS, Jang JY, Han Y, Lee KB, Joo I, Lee DH et al. Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer. Annals of Surgical Treatment and Research. 2017;93(4):186–94. https://doi.org/10.4174/astr.2017.93.4.186.CrossRefGoogle Scholar
- 25.Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK et al. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Annals of Surgery. 2018. https://doi.org/10.1097/SLA.0000000000002753.
- 26.Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199. https://doi.org/10.1186/1471-2407-12-199.CrossRefGoogle Scholar
- 27.Joo I, Lee JM, Lee ES, Ahn SJ, Lee DH, Kim SW et al. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. AJR: American Journal of Roentgenology. 2018;210(5):1059–65. https://doi.org/10.2214/AJR.17.18310.CrossRefGoogle Scholar
- 28.Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Annals of Surgery. 2015;261(1):12–7. https://doi.org/10.1097/SLA.0000000000000867.CrossRefGoogle Scholar
- 30.Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R et al. Alliance for Clinical Trials in Oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017;17(1):505. https://doi.org/10.1186/s12885-017-3441-z.CrossRefGoogle Scholar